SKYE
Price:
$1.21
Market Cap:
$38.77M
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Industry
Biotechnology
IPO Date
2014-11-26
Stock Exchange
NASDAQ
Ticker
SKYE
According to Skye Bioscience, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.93. This represents a change of -77.33% compared to the average of -4.10 of the last 4 quarters.
The mean historical PE Ratio of Skye Bioscience, Inc. over the last ten years is -0.06. The current -0.93 PE Ratio has changed 155.50% with respect to the historical average. Over the past ten years (40 quarters), SKYE's PE Ratio was at its highest in in the June 2016 quarter at 4.27. The PE Ratio was at its lowest in in the March 2024 quarter at -19.77.
Average
-0.06
Median
-1.64
Minimum
-3.89
Maximum
16.56
Discovering the peaks and valleys of Skye Bioscience, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 667.80%
Maximum Annual PE Ratio = 16.56
Minimum Annual Increase = -704.61%
Minimum Annual PE Ratio = -3.89
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -3.89 | 667.80% |
| 2023 | -0.51 | 24.27% |
| 2022 | -0.41 | -83.58% |
| 2021 | -2.48 | 76.32% |
| 2020 | -1.41 | -108.49% |
| 2019 | 16.56 | -704.61% |
| 2018 | -2.74 | 84.68% |
| 2017 | -1.48 | -17.62% |
| 2016 | -1.80 | -26.48% |
| 2015 | -2.45 | -91.77% |
The current PE Ratio of Skye Bioscience, Inc. (SKYE) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-1.60
5-year avg
-1.74
10-year avg
-0.06
Skye Bioscience, Inc.’s PE Ratio is greater than Aligos Therapeutics, Inc. (-1.21), greater than Xilio Therapeutics, Inc. (-2.53), greater than Mersana Therapeutics, Inc. (-1.95), greater than INmune Bio, Inc. (-1.00), less than X4 Pharmaceuticals, Inc. (-0.28), less than Kezar Life Sciences, Inc. (-0.65), less than Barinthus Biotherapeutics plc (-0.39), greater than LAVA Therapeutics N.V. (-1.65), greater than PDS Biotechnology Corporation (-1.20), greater than CEL-SCI Corporation (-1.03),
| Company | PE Ratio | Market cap |
|---|---|---|
| -1.21 | $62.09M | |
| -2.53 | $38.90M | |
| -1.95 | $137.32M | |
| -1.00 | $49.98M | |
| -0.28 | $43.35M | |
| -0.65 | $45.77M | |
| -0.39 | $29.44M | |
| -1.65 | $45.77M | |
| -1.20 | $43.78M | |
| -1.03 | $43.22M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Skye Bioscience, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Skye Bioscience, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Skye Bioscience, Inc.'s PE Ratio?
How is the PE Ratio calculated for Skye Bioscience, Inc. (SKYE)?
What is the highest PE Ratio for Skye Bioscience, Inc. (SKYE)?
What is the 3-year average PE Ratio for Skye Bioscience, Inc. (SKYE)?
What is the 5-year average PE Ratio for Skye Bioscience, Inc. (SKYE)?
How does the current PE Ratio for Skye Bioscience, Inc. (SKYE) compare to its historical average?